HemaSphere

3.0(top 20%)

impact factor

6.0K(top 5%)

papers

5.9K(top 20%)

citations

33(top 20%)

h-index

3.5(top 10%)

extended IF

8.8K

all documents

7.9K

doc citations

45(top 20%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal	HemaSphere	2021	128
2	CAR T Cell Toxicity: Current Management and Future Directions	HemaSphere	2019	121
3	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults	HemaSphere	2018	91
4	In the Eye of the Storm: Immune‐mediated Toxicities Associated With CAR‐T Cell Therapy	HemaSphere	2019	80
5	LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone	HemaSphere	2018	74
6	Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020	HemaSphere	2020	74
7	23rd Congress of the European Hematology Association Stockholm, Sweden, June 14‐17, 2018	HemaSphere	2018	72
8	Anemia in the Elderly	HemaSphere	2018	71
9	Erythroferrone: An Erythroid Regulator of Hepcidin and Iron Metabolism	HemaSphere	2018	60
10	Hypoferremia is Associated With Increased Hospitalization and Oxygen Demand in COVID‐19 Patients	HemaSphere	2020	58
11	EHA2021 Virtual Congress Abstract Book	HemaSphere	0	56
12	From Biology to Therapy: The CLL Success Story	HemaSphere	2019	55
13	Mesenchymal Stromal Cells: Role in the BM Niche and in the Support of Hematopoietic Stem Cell Transplantation	HemaSphere	2018	53
14	Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study	HemaSphere	2021	52
15	Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up	HemaSphere	2019	51
16	Advances in B‐cell Precursor Acute Lymphoblastic Leukemia Genomics	HemaSphere	2018	49
17	JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives	HemaSphere	2020	49
18	2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia	HemaSphere	2022	49
19	Abstract Book for the 27th Congress of the European Hematology Association	HemaSphere	0	46
20	Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments	HemaSphere	2021	45
21	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up	HemaSphere	2021	45
22	Azacytidine Treatment for VEXAS Syndrome	HemaSphere	2021	45
23	The Complexity of Genotype‐Phenotype Correlations in Hereditary Spherocytosis: A Cohort of 95 Patients	HemaSphere	2019	43
24	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report	HemaSphere	2019	43
25	CAR‐T Cells: Future Perspectives	HemaSphere	2019	43
26	The Emerging Role of Convalescent Plasma in the Treatment of COVID‐19	HemaSphere	2020	42
27	Myeloid‐Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets	HemaSphere	2019	41
28	Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group	HemaSphere	2018	40
29	Chronic Myeloid Leukemia in 2020	HemaSphere	2020	40
30	Hemophilia Gene Therapy: Approaching the First Licensed Product	HemaSphere	2021	40
31	Long‐term Outcomes in Patients With Multiple Myeloma	HemaSphere	2018	38
32	Myelofibrosis‐Related Anemia	HemaSphere	2017	37
33	Longitudinal Cytokine Profiling Identifies GRO‐α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia	HemaSphere	2020	37
34	Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow‐up Samples From Four Prospective Trials of the European MCL Network	HemaSphere	2020	36
35	COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma	HemaSphere	2021	35
36	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party	HemaSphere	2022	35
37	CAR T Cells: A Snapshot on the Growing Options to Design a CAR	HemaSphere	2019	34
38	Rituximab With Involved Field Irradiation for Early‐stage Nodal Follicular Lymphoma	HemaSphere	2018	33
39	Insights on Multiple Myeloma Treatment Strategies	HemaSphere	2019	33
40	CAR‐T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope	HemaSphere	2019	33
41	Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?	HemaSphere	2019	33
42	Long Term Follow‐up Data and Health‐Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)	HemaSphere	2020	31
43	Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group	HemaSphere	2020	31
44	SARS-CoV-2 Vaccines in Patients With Multiple Myeloma	HemaSphere	2021	31
45	Chimeric Antigen Receptor‐T Cell Therapy	HemaSphere	2018	30
46	Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies	HemaSphere	2021	29
47	EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19	HemaSphere	2021	29
48	Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma	HemaSphere	2020	29
49	EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer	HemaSphere	2022	29
50	Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management	HemaSphere	2020	28

Scientometrics

Overviews

Citing Bodies

HemaSphere

Top Articles